Fig. 3: Genome-wide effect of felzartamab treatment on kidney allograft biopsy gene expression. | Nature Medicine

Fig. 3: Genome-wide effect of felzartamab treatment on kidney allograft biopsy gene expression.

From: Effect of felzartamab on the molecular phenotype of antibody-mediated rejection in kidney transplant biopsies

Fig. 3

a–c, The effect of felzartamab treatment on gene expression (ΔΔlogFC) from baseline to week 24 (a), week 24 to week 52 (b) and baseline to week 52 (c). The circles represent the ΔΔlogFC (y-axis) and P values (x-axis) of individual genes compared between biopsies from placebo (npatients = 10) and felzartamab (npatients = 10) arms from baseline to week 24, and week 24 to week 52. All biopsies represent biological replicates. Functional enrichment by differentially expressed genes is included in a–c. The gene labels represent the top ten genes by representation across all enrichment terms. d–f, The effect of felzartamab on IFNγ-inducible ABMR activity genes (d), NK cell-expressed ABMR activity genes (e) and ABMR-associated endothelial genes (f). Data in d–f are represented as fold change ± empirical Bayes moderate standard errors in fold change calculated using moderated Bayes t-tests.

Back to article page